Investigating how a specific protein affects B cell activation and lymphoma development
Roles of Coactivator-Associated Arginine Methyltransferase 1 in B cell activation and lymphomagenesis
This study is looking at how a protein called CARM1 affects B cells and certain types of lymphomas, like follicular lymphoma and diffuse large B cell lymphoma, to find out if changes in genes related to this protein can help us develop new, less harmful treatments for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11056689 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a protein called CARM1 in the activation of B cells and the development of certain types of lymphomas, particularly follicular lymphoma and diffuse large B cell lymphoma. The study aims to explore how mutations in genes related to this protein can influence the behavior of these cancers, which often start slowly but can become aggressive. By analyzing genetic changes and their effects on B cell function, the research seeks to identify potential new therapies that are less toxic than current treatments. Patients may be involved in trials that test these new targeted therapies based on the findings.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients diagnosed with follicular lymphoma or diffuse large B cell lymphoma, especially those who have not responded well to standard treatments.
Not a fit: Patients with other types of cancers or those who do not have B cell lymphomas may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of less toxic and more effective treatments for patients with B cell lymphomas.
How similar studies have performed: Other research has shown promise in targeting epigenetic modifications in lymphomas, indicating that this approach could be beneficial.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Santos, Margarida — University of Tx Md Anderson Can Ctr
- Study coordinator: Santos, Margarida
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.